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ABSTRACT 
     Multiple sclerosis (MS) is an inflammatory demyelinating disease which the exact etiology is still are 
far to be clear. Reasons for this autoimmune disease are unknown origin. The aim of present study was 
to evaluate serum levels of selenium in patient with MS compare to healthy subjects. A total of 46 
subjects were enrolled in the study, Sera of 23 MS cases and 23 healthy normal cohorts as control group 
were obtained. Atomic absorption spectrophotometer was employed for estimating serum selenium level. 
Serum selenium levels were significantly lower in MS than in control cohorts (60.87±13 compared with 
85.74±12, P-value < 0.0001). Serum selenium levels may thus be a marker of MS; the decreasing levels 
of serum selenium may be host defense strategies of body.  
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INTRODUCTION  
Multiple sclerosis (MS) is considered as an 
autoimmune disease; the reason of this 
progressive demyelinating pathology is still not 
completely understood [1, 2]. A series of 
biochemical changes characterize in MS as with 
the other neurodegenerations. Diverse extent 
neuronal functions affect these changes. Such 
the changes can be pointed out: great attention 
has been given to oxidative/nitrosative stress 
[3]. A series of biochemical changes are in 
common with other neurodegenerations such as 
Alzheimer’s and Parkinson’s diseases. At 
molecular point of view, biochemical changes 
affect on neuronal functions [4].  
One of these biochemical changes is the 
neuronal imbalance in reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) 
[5,6]. ROS are a number of reactive molecules 
and free radicals derived from molecular 
oxygen. ROS are as byproducts of during the 
mitochondrial electron transport of aerobic 
respiration. Also oxidoreductase enzymes 
generate these molecules. 
Similarly to ROS, RNS are products of normal 
cellular metabolism. ROS and RNS can be 
either harmful or beneficial to living systems  
 
[7]. The deleterious role of these species cause 
potential biological damage, oxidative stress 
and nitrosative stress [8].  
As antioxidant, selenium can scavenge ROS and 
RNS. Selenium is a trace element in small 
amounts in the body. It combined with vitamin 
E and plays a role as an antioxidant. 
Antioxidants can be eliminated damaging 
particles in the body like free radicals, ROS and 
RNS; they neutralize free radicals. These 
damaging species may contribute to aging, heart 
disease and cancer. Antioxidants can help to 
prevent some of the damage of ROS and RNS. 
Consistent with role antioxidant of selenium in 
the body, immune system requests it to perform 
correctly. 
Low levels of selenium may cause a number of 
conditions example some types of cancer. These 
properties of selenium may suggest that 
selenium deficiency is associated with an 
increased probability of developing MS [9].  
The aim of the present study was to investigate 
prospectively the serum level of selenium in 








MATERIALS AND METHODS 
Measurement of serum selenium levels 
A total of 46 subjects were included in this 
study: 23 MS positive patients (9 males and 14 
females with mean age of 33 ±standard 
deviation of 11 years) and 23 healthy (8 males 
and 15 females with mean age 35± standard 
deviation of 12years).  
Samples were recruited from the Firoozgar 
hospital in Tehran. All patients were informed 
about the study and written consent was signed 
by the patients and control group. Serum 
samples were obtained in the morning after 12-
hours overnight fast. With the purpose of 
coagulate serum samples; vials were stored at 
room temperature (20-28°C). Often in 20-30 
minutes clot formation is completed. Then 
serum was separated by 10 minutes of 
centrifugation at 2500 rpm. Finally  samples 
were frozen at -20
o
C until use [10]. 
Statistical analysis  
The statistical analysis was performed using the 
Fisher exact test and χ2. A P value of less than 
0.05 was considered statistically significant. 
Also a one way one-way analysis of variance 
(ANOVA) test use to compare groups or 
conditions in an experiment.  
 
RESULTS  
In this study, selenium concentrations in 23 
patients suffering from MS disease were 
measured and compared with 23 normal control 
subjects. Table 1 is as ANOVA table. This table 
includes six columns that last column state p-
value. In accordance with Table 1, 
P-value is less than 0.0001. Consequently, the 
null hypothesis of equal means is false, p-value 
declare the two mean difference was 
statistically significant when we compare the 
two groups.  
Figure 1 represents box plot for two cohorts. 
Great values of F and small values of p-values 
conclude large difference in the center lines of 
the boxes. The mean serum level of selenium in 
MS patients was determined by atomic 
absorption spectroscopy and the results are 
60.87±13 μg/l and 85.74±12 μg/l for MS and 




Table 1. ANOVA Table for two cohorts of MS and healthy subject* 
Source SS DF MS F Prob>F 
Columns 7112.7 1 7112.7 41.71 7.14e-008 
Error 7503 44 170.52   
Total 14615.7 45    








The serum selenium levels of the MS patients in 
our study were significantly lower than those of 
the healthy controls. Therefore selenium is 
sometimes suggested for subjects with MS. The 
reason for this suggestion may be selenium is an 
antioxidant and MS subjects have low selenium 
levels. Selenium is an essential for activity of 
glutathione peroxidase (GSHPx). 
This enzyme is catalyses of reaction the 
oxidation of reduced glutathione to form 
oxidized glutathione and water [11, 12]. Based 
on the results of Drowkin et al. [13] low level of 
selenium considerably reduces GSH-Px 
activities levels in acquired immunodeficiency 
syndrome (AIDS). Hence an important 
correlation is between selenium and GSH-Px in 
AIDS. In another study, Kocyigit et al. [14] 
found that there was a good correlation between 
blood selenium values and GSH-Px activity. As 
previously mentioned, selenium is a component 
 




of glutathione peroxidase. Vitamin E and 
selenium worked together to protect against the 
harmful effects of peroxide and free radicals. 
Selenium can bind cadmium, mercury and other 
metals and acts as an anti-toxic element. By this 
work it alleviates toxic effects cadmium and 
mercury [15].  In our study, it was demonstrated 
that the serum selenium level in MS subjects 
decrease compared with the control group. The 
explanation for this reduction can be searched 
features of antioxidant related to selenium. It 
has an essential role in the regulation of the 
immune system. As explained in the previous 
paragraph, selenium has been found at the 
active sites of the enzymes which are involved 
in the oxidation reduction reaction [16].  
This antioxidant is  in the extracellular space 
and in the cell cytosol, in association with the 
cell membranes. These parts can be the possible 
to influence the immune processes [17]. 
Selenium has a protective effect against 
oxidative stress. 
In summary, we conclude that selenium play a 
role in the pathophysiologic processes of MS. In 
order to properly define the role of selenium in 
patients with MS, extensive studies are needed.  
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